Gene Logic Recruits Pharmaceutical Executive as Senior Vice President of Clinical Development
31 Juli 2007 - 7:00PM
Business Wire
Gene Logic Inc. (NASDAQ:GLGC) announced today the appointment of
Stephen R. Donahue, M.D. as Senior Vice President of Clinical
Development. Dr. Donahue will lead the Company�s efforts in
clinical development to advance proprietary drug candidates it
acquires through drug repositioning partnerships. Dr. Donahue�s
responsibilities will integrate with those of Gene Logic�s
Rediscovery and Business Development and Licensing groups to drive
the growth of the Company�s emerging business in Drug
Repositioning. Dr. Donahue�s background includes all phases of
clinical drug development and regulatory affairs. He holds board
certifications in both Internal Medicine and Clinical Pharmacology.
Prior to his appointment at Gene Logic, Dr. Donahue was Vice
President, Clinical Research and Operations, at Epix
Pharmaceuticals, Inc., a Massachusetts-based, clinical-stage
biopharmaceutical company. Before Epix, Dr. Donahue served with
Merck & Co., Inc. as Medical Director, Clinical Research,
Atherosclerosis and Metabolism. Prior to Merck, he held positions
of increasing responsibility with Bristol-Myers Squibb, including
in the departments of Clinical Design and Evaluation, and Clinical
Pharmacology/Experimental Medicine. He has developed drugs in
several different therapeutic areas and has worked on products such
as Vytorin�, Pravachol�, and Glucophage�. Dr. Donahue holds an M.D.
from Georgetown University, and was an NIH Fellow in Clinical
Pharmacology at Georgetown University Medical Center. Charles L.
Dimmler, III, Gene Logic Chief Executive Officer and President,
said, �Gene Logic�s drug repositioning efforts are proceeding on
plan with more than 70 compounds under evaluation. An initiative is
underway now to secure a development partner for the Company�s
first proprietary drug candidate, GL1001, acquired from Millennium
Pharmaceuticals. Stephen Donahue has proven expertise in clinical
development and will be a key figure as we continue to execute Gene
Logic�s strategic plan.� Stephen R. Donahue, M.D., Senior Vice
President, Clinical Development for Gene Logic, said, �I�m pleased
to be joining Gene Logic at a time when the Company�s Drug
Repositioning Program and partnerships with Pfizer, Roche, Abbott,
Eli Lilly, Organon, and Lundbeck offer exciting opportunities for
clinical development of novel drug candidates in a variety of
therapeutic areas. I look forward to applying my clinical
development expertise to the development of GL1001 and future Gene
Logic drug candidates.� VYTORIN� is a registered trademark of MSP
Singapore Company, LLC. PRAVACHOL� and GLUCOPHAGE� are registered
trademarks of Bristol-Myers Squibb Company or one of its divisions
or subsidiaries. Gene Logic Overview Gene Logic is transforming
into a pharmaceutical development company through partnerships with
pharmaceutical companies. Our partners provide Gene Logic with
access to their drug candidates that have been assessed as safe in
human clinical trials but discontinued for other reasons. Gene
Logic applies its drug indication platform to find new therapeutic
uses for the drug candidates. Gene Logic expects to receive
milestone payments and royalties on drug candidates that our
partners choose to develop based on the indications we find or, if
the partner elects not to pursue such new indications, Gene Logic
may receive ownership and development rights. Gene Logic has also
developed proprietary genomics databases and services to enable
customers worldwide to discover and prioritize drug targets,
identify biomarkers, predict toxicity and understand mechanisms of
toxicity, and obtain insights into the efficacy of specific
compounds. We continue to offer customers these services and
licenses to the databases. Such databases, services and expertise
are also a vital part of our drug indication platform. Following
consideration of various strategic alternatives for its Genomics
Division, the Company is concentrating its efforts on investigating
the possibility of a sale of all or parts of its Genomics business
while continuing to serve new and existing Genomics customers.
Founded in 1994, Gene Logic is headquartered in Gaithersburg, Md.,
with additional research and development facilities in Cambridge,
Mass. The Company currently has about 150 employees worldwide. For
more information, visit www.genelogic.com or call toll-free �
1/800/GENELOGIC.
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Gene Logic Inc. (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Gene Logic Inc. News-Artikel